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Total and HDL cholesterol and risk of stroke.
EUROSTROKE: a collaborative study among research
centres in Europe
M L Bots, P C Elwood, Y Nikitin, J T Salonen, A Freire de Concalves, D Inzitari,
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Background: Controversy remains on the relation between serum lipids levels and stroke risk. This
paper investigated the association of total and HDL cholesterol level to fatal and non-fatal, and haem-
orrhagic and ischaemic stroke in four European cohorts participating in EUROSTROKE.
Methods: EUROSTROKE is a collaborative project among ongoing European cohort studies on
incidence and risk factors of stroke. EUROSTROKE is designed as a nested case-control study. For each
stroke case, two controls were sampled. Strokes were classified according to MONICA criteria or
reviewed by a panel of four neurologists. At present, data on stroke and risk factors were available
from cohorts in Cardiff (84 cases), Kuopio (74 cases), Rotterdam (157 cases), and Novosibirsk (79
cases).
Results: Pooled analyses showed no significant association between total cholesterol and risk of stroke
(odds ratio for increase of 1 mmol/l in cholesterol of 0.98 (95% CI 0.88 to 1.09)). Analyses for haem-
orrhagic stroke and cerebral infarction revealed odds ratios of 0.80 (95% CI 0.61 to 1.05) and 1.06
(95% CI 0.94 to 1.19), respectively. The association of HDL cholesterol to stroke was different in men
compared with women. In men, there was a general trend towards a lower risk of stroke with an
increase in HDL (odds ratio per 1 mmol/l increase in HDL cholesterol 0.68 (95% CI 0.40 to 1.16)). In
women, however, an increase in HDL was associated with a significant increased risk of non-fatal
stroke and of cerebral infarction (odds ratios of 2.46 (95% 0.1.20 to 5.04) and 2.52 (95% CI 1.15
to 5.50), respectively. The difference between men and women in the association of HDL with stroke
seemed to differ mainly in smokers and never smokers, but not among ex smokers.
Conclusion: This analysis of the EUROSTROKE project could not disclose an association of total chol-
esterol with fatal, non-fatal, haemorrhagic or ischaemic stroke. HDL cholesterol however, seemed to be
related to stroke differently in men than in women.
There is abundant evidence indicating that increased levelsof total cholesterol and low levels of HDL cholesterol arestrong and important risk factors for coronary atheroscle-
rosis and symptomatic coronary heart disease. Furthermore,
recent guidelines have emphasised the use of serum lipid
measurements in the prevention of coronary heart disease.1
The evidence on the association of cholesterol and stroke has
been more controversial. Compared with coronary heart
disease, stroke is a more heterogeneous disease and comprises
at least three main types: subarachnoid haemorrhage, cerebral
haemorrhage, and cerebral infarction. Each type of stroke may
have a different aetiology, and thus may have different or even,
partly competitive risk factors that cause the stroke to occur.2–5
Therefore, the association between cholesterol and stroke may
not be as straightforward as for coronary heart disease.
Prospective population-based studies have yielded equivo-
cal results. Some have reported a direct association with total
cholesterol and total stroke,6 or cerebral infarction,7–10 others
showed little or no association with total stroke11 or cerebral
infarction.12 13 Some demonstrated an inverse relation between
total cholesterol and death from haemorrhagic stroke.8 14 The
only three available prospective population-based studies on
the association between HDL cholesterol and risk of stroke
showed a tendency towards a higher risk of cerebral infarction
with a lower HDL level.15 16
We set out to evaluate the association between total and
HDL cholesterol and fatal, non-fatal, haemorrhagic and
ischaemic stroke using data from four European cohorts par-
ticipating in EUROSTROKE.
METHODS
The rationale and design of EUROSTROKE have been
described in detail elsewhere.17 In short, EUROSTROKE is a
collaborative study among European research centres to
investigate (1) the variation in incidence of fatal and non-fatal
ischaemic and haemorrhagic stroke among populations in
different European countries; (2) whether the observed
differences in stroke incidence across countries can be
explained by differences in prevalence of established cardio-
vascular risk factors; (3) the relative importance of smoking
and some selected dietary factors (potassium intake, alcohol
consumption), haemostatic disturbances (fibrinogen) and
comorbidity (rheumatic heart disease, atrial fibrillation) com-
pared with established risk factors as determinants of the
occurrence of ischaemic and haemorrhagic stroke. The
EUROSTROKE database is drawn from ongoing European
population-based prospective follow up studies (cohorts) and
is designed as a case-control study nested within these ongoing
studies. For each stroke case, two controls were sampled.
Controls were matched on day of baseline examination only.
Apart from its objectives, the EUROSTROKE database allows
for aetiological analyses looking into various risk factors for
stroke. EUROSTROKE formally started on 1 January 1994. At
present, data from four cohorts were available for analysis.
Finland
The Finnish contribution to EUROSTROKE comes from the
Kuopio Ischaemic Heart Disease Risk Factor study, which is a
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population-based prospective cohort study comprised of an
age stratified random sample of 2682 men aged 42, 48, 54 and
60 years. The baseline examination was performed between
1984 and 1989.18 Fatal and non-fatal stroke cases were
collected through the national mortality statistics and the
FINMONICA stroke registries. Stroke was defined according
to FINMONICA criteria and definitions.19 Case ascertainment
from the baseline examination to 1 January 1993 revealed 74
stroke cases. Controls subjects (n=148) were randomly drawn
from the cohort that remained free from stroke during follow
up.
The Netherlands
The Dutch contribution to EUROSTROKE comes from the
Rotterdam Study, which is a population-based prospective fol-
low up study among 7983 subjects, aged 55 years or over, liv-
ing in the suburb of Ommoord in Rotterdam, the
Netherlands.20 Baseline data were collected from March 1990
to July 1993. In the Rotterdam Study, information on incident
fatal and non-fatal events is obtained from the general practi-
tioners (GPs) working in the study district of Ommoord as
described earlier.21 The GPs involved report all possible cases of
stroke to the Rotterdam research centre. Events are presented
in coded information following the International Classifi-
cation of Primary Care (ICPC).22 With respect to the vital sta-
tus of the participants, information is obtained at regular
intervals from the municipal authorities in Rotterdam and
also death of a participant is reported as code A96 by GPs.
When an event or death has been reported, additional
information is obtained by interviewing the GP and scrutinis-
ing information from hospital discharge records in case of
admittance or referral. All suspected cerebrovascular events
reported by the GPs were submitted for review to the EURO-
STROKE case review board. From baseline to December 1994,
192 stroke cases were identified and submitted for review and
a total of 384 control subjects were drawn from the remainder
of the cohort that remained free from stroke during follow up.
A total of 157 events were classified as definite or probable
strokes.
Russia
The Russian contribution to EUROSTROKE comes from stud-
ies performed in the Octyabrsky, the Kirovsky and Leninsky
districts of Novosibirsk, Siberia. The Novosibirsk cohort is
based on three population-based surveys, which were
conducted between 1984 and 1989 as part of the WHO
MONICA project.23 The Novosibirsk cohort comprises 9006
men and women aged 25 to 64 years. Stroke cases were
collected through a specifically developed stroke registry, aim-
ing to identify fatal and non-fatal hospitalised and non-
hospitalised stroke patients.24 25 Stroke events were defined
according to MONICA criteria and definitions.26 From baseline
to December 1995, a total of 100 stroke cases had been identi-
fied and 200 control subjects were drawn from the database.
Finally, 79 subjects proved to be true strokes.
United Kingdom
The British contribution to EUROSTROKE comes from the
Caerphilly Heart Disease study in Wales, United Kingdom, in
which 2512 men, aged 45 to 59 years are participating.27 Base-
line examinations took place from 1979 to 1983. Follow up
examinations were performed from 1984 to 1988 (phase II)
and from 1989 to 1993 (phase III). Stroke events were
registered through national mortality statistics, hospital
discharge records, self report and family report. Of the
registered events, additional information on signs and symp-
toms, on neuroimaging, necropsy and a copy of the discharge
records were collected. When complete, stroke cases were
submitted for review to the EUROSTROKE case review board
as described earlier. On 1 December 1996, 100 stroke events
had been submitted for review and 200 controls subjects had
been drawn from the remaining cohort. Eighty four stroke
cases were classified as definite/probable stroke by the
EUROSTROKE review board.
EUROSTROKE case review board
The review board comprised of four Dutch neurologists. Based
on all information, including symptoms and signs obtained by
interviewing the GP or, in case of hospital referral, hospital
data, the neurologists classified the events as definite,
probable and possible stroke. Events were classified by two
neurologists. In case of disagreement a third neurologist was
consulted, whose opinion was decisive for the final classifi-
cation. The present analysis is restricted to definite and prob-
able events, outcomes in which a stroke most probably did
occur according to the neurologist’s opinion. For the present
analysis an incident stroke was considered to have occurred
when (1) the event had led to a hospitalisation and the hospi-
tal discharge record indicated a diagnosis of a new stroke. The
clinical diagnosis was based on signs and symptoms, and
neuroimaging investigations during hospital stay (definite
stroke); or (2) in case of no hospitalisation, signs and
symptoms associated with the event obtained from the GP
records and interview were highly suggestive of a stroke
according to the neurologists (probable stroke) or (3) in case
of out hospital death, when the GPs reported that the cause of
death was a cerebrovascular accident and a cardiac cause was
judged by the GP to be highly unlikely (probable stroke).
The event was classified into first and recurrent stroke and
into subarachnoid haemorrhage, intracranial haemorrhage,
intracerebral infarction, and unspecified (not documented).
For the non-MONICA centres (the Netherlands, United King-
dom) ischaemic stroke was further classified into lacunar inf-
arct; total anterior circulation infarct; partial anterior circula-
tion infarct; posterior circulation infarct and unspecified
infarct (undocumented). The classification was made follow-
ing the guidelines described by Bamford and coworkers28 and
by the European Atrial Fibrillation Trial.29
Cardiovascular risk factors
As EUROSTROKE is based on ongoing cohort studies,
information on cardiovascular risk factors in each of the par-
ticipating centres was already being collected before the
EUROSTROKE project was established.Whenever possible, an
exhaustive attempt was made to further harmonise the
collected information to make comparison across studies pos-
sible. Nevertheless, baseline measurements could not be
standardised beyond the attempts done in each individual
study.
In each of the centres information on smoking, alcohol
consumption, and medial history was obtained by question-
naire. The subject’s smoking behaviour was categorised into
current, former or never. Alcohol consumption was catego-
rised into current drinkers and non-current drinkers (former
and never). In addition, an estimate of grams of alcohol per
day was obtained. Presence of diabetes mellitus was generally
based on the question “Do you suffer from diabetes mellitus?”.
In the Rotterdam study diabetes mellitus was considered
present when subjects used blood sugar lowering drugs,
whereas in the Novosibirsk study presence of diabetes mellitus
Key points
• EUROSTROKE is based on population-based ongoing
cohort studies.
• Total cholesterol is not associated with risk of stroke nor
with cerebral infarction.
• Increased HDL cholesterol might be related to stroke in
women, whereas in men an increased relation is not found.
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was not evaluated for the entire cohort. Information on a his-
tory of stroke was obtained by direct questioning at baseline
“Did you ever suffer from a stroke?”. A similar approach was
taken for myocardial infarction. Presence of angina pectoris
was based on either the cardiovascular Rose questionnaire or
direct questioning.
In general, systolic and diastolic blood pressure were
measured twice at one occasion in sitting position. In Cardiff,
only one blood pressure measurement was performed. Height
and weight were measured and body mass index (kg/m2) was
calculated. In all four centres an electrocardiogram was made
and the presence of a Q-wave myocardial infarction and left
ventricular hypertrophy were assessed according to the
Minnesota classification system, or in Rotterdam, by using the
automated diagnostic classification system of the Modular
Electrocardiogram Analysis System (MEANS).30 31 Apart from
Rotterdam, a fasting blood sample was taken for determina-
tion of serum lipids (total cholesterol, HDL cholesterol).
Serum total cholesterol level was determined with an
automatic analyser using enzymatic procedures in
Rotterdam,32 in Cardiff,33 in Finland,34 and Novosibirsk.35
Data analysis
The analyses were first performed for each centre separately.
To identify potential confounding variables, cardiovascular
risk factors were related to stroke using logistic regression
models and to cholesterol using linear regression models. Fac-
tors that were related to both stroke and cholesterol (p<0.10),
and that were not assumed to be in the causal pathway of
cholesterol leading to stroke were considered confounding
variables. Systolic blood pressure, diastolic blood pressure,
body mass index, current smoking, and diabetes mellitus were
evaluated as potential confounders. Cholesterol level as
predictor of stroke was studied as a continuous variable using
logistic regression analysis. Initially adjustments were made
for age, and subsequently for potential confounding cardio-
vascular risk factors.
An interaction term (cholesterol × centre) was used to study
whether the association between level of cholesterol and
stroke differed across the four centres. Similarly, an interac-
tion term (cholesterol × sex) was used to evaluate whether the
association differed between men and women. Results are
presented as odds ratios, with their corresponding 95% confi-
dence intervals (95% CI).
In the analyses in which information from all four centres
was combined (pooled analyses) cholesterol was studied as a
continuous variable and in quartiles based on the pooled
cholesterol distribution. Logistic regression analysis was used
(with three dummy variables) to evaluate the association
between level of cholesterol and stroke.Adjustments were first
made for age and subsequently for cardiovascular risk factors.
Separate analyses were performed for total stroke, first ever
stroke, fatal stroke (death within 28 days after onset),
non-fatal stroke, and for haemorrhagic stroke and cerebral
infarction.
Because it has been suggested that the association between
total cholesterol and stroke may be present only at the
extremes of the total cholesterol distribution,7 we performed
additional analyses in strata of total cholesterol (<5.0, 5.0–5.9,
6.0–6.9, 7.0–7.9,>8.0 mmol/l).
RESULTS
General characteristics of the studied populations are given in
table 1. Characteristics of the events are presented in table 2.
Some 73% of the strokes were hospitalised, where of all
strokes 55% had neuroimaging performed (CT/MRI). In the
pooled analyses systolic blood pressure, diastolic blood
pressure, current smoking, body mass index, and history of
diabetes mellitus were positively, and significantly related to
stroke. Body mass index showed a strong significant positive
association with cholesterol level, whereas systolic blood pres-
sure, body mass index, and diabetes mellitus were inversely
related to HDL cholesterol and thus these factors were consid-
ered as a confounders.
The statistical significance (p value) of interaction terms to
evaluate whether the association between cholesterol and
stroke differed across the four centres was 0.68 for total chol-
esterol and 0.13 for HDL cholesterol. The p value of the inter-
action term for sex was 0.19 for total cholesterol and 0.016 for
HDL cholesterol. Therefore, the results for HDL cholesterol are
presented for men and women separately. No interaction was
found for diabetes or hypertension.
Table 1 General characteristics of the study population
Characteristic Cardiff, UK Kuopio, FIN Rotterdam, NL Novosibirsk, RUS All
Case/control 80/195 72/143 127/376 67/191 346/905
Age (y) 57.6 (5.9) 55.2 (4.1) 72.8 (10.1) 51.6 (9.1) 62.1 (12.2)
Female (%) * * 64.2 40.7 34.2
Systolic pressure (mm Hg) 146 (22) 132 (18) 144 (24) 144 (25) 143 (24)
Diastolic pressure (mm Hg) 86.4 (12.7) 88.7 (10.4) 74.2 (12.9) 93.1 (13.9) 83.6 (14.8)
Total cholesterol (mmol/l) 5.8 (1.2) 6.1 (1.2) 6.6 (1.3) 5.8 (1.3) 6.2 (1.3)
HDL cholesterol (mmol/l) 1.05 (0.33) 1.26 (0.28) 1.34 (0.37) 1.27 (0.38) 1.26 (0.36)
Current smoking (%) 46.1 27.9 23.0 34.1 31.2
Body mass index (kg/m2) 26.6 (3.6) 26.9 (3.4) 26.1 (3.6) 28.4 (5.4) 26.9 (4.1)
Diabetes mellitus (%) 4.4 6.5 8.8 NA† 6.6
Values are unadjusted proportions or means with standard deviations in parentheses of all subjects. *Only men participated in the study; †NA=not
assessed.
Table 2 Stroke characteristics of the participating centres
Characteristic
Cardiff,
UK
Kuopio,
FIN
Rotterdam,
NL
Novosibirsk,
RUS Pooled
Total stroke 80 72 127 67 346
Fatal 22 14 33 17 86 (24.9)
Non-fatal 58 58 94 50 260 (75.1)
Haemorrhagic 10 15 12 10 47 (13.6)
Ischaemic 56 52 76 51 235 (67.9)
Unspecified 14 5 39 6 64 (18.5)
Values are absolute numbers with percentages in parentheses.
Total and HDL cholesterol and risk of stroke i21
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The association of total cholesterol to stroke for each centre
is given in figure 1. In all centres non-significant associations
were seen without evidence for heterogeneity. The pooled
analyses with total cholesterol level in quartiles are presented
in table 3. Total cholesterol was not associated with an
increased risk of any type stroke. There was a suggestion of a
reduced risk of haemorrhagic stroke among those with total
cholesterol levels in the upper quartile of the distribution rela-
tive to those at the lower quartile of the distribution. Subjects
with cholesterol levels of 8.0 mmol/l or above were not at a
significantly increased risk of total stroke nor of cerebral inf-
arction relative to those with levels of 5 mmol/l or lower. Rela-
tive to subjects with total cholesterol levels below 5.0 mmol/l,
the age, sex and body mass index adjusted risks of cerebral
infarction were 0.88, 1.29, 1.26, and 0.93 for subjects with total
cholesterol levels of 5.0–5.9, 6.0–6.9, 7.0–7.9 and>8.0 mmol/l.
In men, an increase in HDL cholesterol was associated with
a non-significant reduced risk of stroke in all centres (fig 2). In
the pooled analyses among men, HDL cholesterol was not sig-
nificantly associated with an increased risk of stroke, fatal
stroke, non-fatal stroke, and type of stroke although all point
estimates suggest a reduced risk with increasing HDL levels
(table 4). In women, a non-significant increased risk of stroke
with increasing HDL levels was found in both the Rotterdam
and Novosibirsk cohorts (fig 2). The pooled analyses with HDL
cholesterol level in quartiles revealed significant increased
risks of cerebral infarction and non-fatal stroke with increas-
ing HDL levels (table 4).
When analyses were stratified by sex and smoking category
(current, ex, never), it appeared that association of HDL and
stroke were clearly different between men and women in the
current and never smoking groups. The risk of stroke
associated with an 1 mmol HDL increase in current smoking
men (102 cases/189 controls) was 0.72 (0.35 to 1.51), for
women (18 cases/41 controls) an odds ratio of 3.64 (0.92 to
14.4). For never smokers the odds ratio in men (112/317) was
0.50 (0.11 to 2.19) and for women (83/267) 1.47 (0.64 to 3.42).
DISCUSSION
This analysis from the EUROSTROKE project does not support
the presence of an association between total cholesterol and
fatal, non-fatal, haemorrhagic and ischaemic stroke. HDL
cholesterol, however, seemed to be related to stroke differently
in men than in women.
Several aspects of this study should be consiodered. Firstly,
EUROSTROKE is designed as a case-control study. The
proportion of fatal cases across the centres differed from 19%
in Kuopio to 28% in the other centres (table 2), the latter may
be indicative for some underrepresentation of non-fatal cases.
It is not likely that the completeness of non-fatal case
ascertainment is differential across cholesterol levels, al-
though this cannot be verified. Yet, if non-fatal cases have been
selected at a higher level of the exposure of interest, this may
bias a true positive association towards a stronger association,
rather than blur a true positive association towards a null
finding (present results). Secondly, as the number of haemor-
rhagic strokes is limited (n=47), these stroke type specific
results should be interpreted with some caution. Strengths of
this study are the fairly large number of well diagnosed and
classified events for bothmen and women, presence of data on
a large number of potential confounders, a wide age range,
and risk factor assessment before the occurrence of the stroke
event. In addition, we were able to distinguish between differ-
ent subtypes of strokes and thus to evaluate the effect of lipids
on ischaemic stroke.
Recently, the Prospective Studies Collaboration has re-
viewed the association between cholesterol and mortality
from stroke using data obtained in 45 prospective population-
based cohort studies.11 The cause of death in the various stud-
ies varied from death certificates alone, or, in some studies
with additional medical information and/or necropsy find-
ings. A differentiation in type of stroke could not be made, nor
Table 3 Total cholesterol and risk of stroke in quartiles of the cholesterol distribution
Stroke
First quartile Second quartile Third quartile Fourth quartile*
Trend†Cases Cases Cases Cases
All 80 1.0 89 0.97 (0.68 to 1.41) 93 1.32 (0.91 to 1.90) 84 1.02 (0.70 to 1.49) 0.96 (0.86 to 1.07)
Fatal 25 1.0 24 0.73 (0.39 to 1.38) 19 0.78 (0.40 to 1.51) 18 0.60 (0.30 to 1.20) 0.82 (0.67 to 1.00)
Non-fatal 55 1.0 65 1.08 (0.71 to 1.62) 74 1.55 (1.02 to 2.34) 66 1.21 (0.79 to 1.85) 1.01 (0.90 to 1.13)
Haemorrhagic 14 1.0 12 0.80 (0.37 to 1.79) 17 1.28 (0.60 to 2.75) 4 0.29 (0.09 to 0.92) 0.78 (0.61 to 1.02)
Ischaemic 51 1.0 58 1.05 (0.68 to 1.61) 63 1.49 (0.98 to 2.30) 63 1.31 (0.85 to 2.02) 1.05 (0.93 to 1.18)
Ischaemic‡ 66 1.0 77 1.02 (0.69 to 1.51) 76 1.33 (0.90 to 1.98) 79 1.17 (0.79 to 1.74) 0.99 (0.89 to 1.11)
Odds ratios with 95% CI relative to the first quartile of serum total cholesterol, adjusted for age, sex, and body mass index. Number of control subjects in
the respective quartiles were 227, 248, 202 and 228. *Cut off points 5.26, 6.10 and 6.91 mmol/l; †trends: odds ratio per 1 mmol/l increase in total
cholesterol; ‡ischaemic stroke including unspecified stroke events.
Figure 1 Risk of stroke per increase of 1 mmol/l in total
cholesterol, adjusted for age, sex, and body mass index, by centre.
Novosibirsk
2
Odds ratio (95% CI)
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Figure 2 Risk of stroke per increase of 1 mmol/l in HDL
cholesterol, adjusted for age, body mass index, systolic blood
pressure, and diabetes mellitus, by centre (top for men, bottom for
women).
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were analyses presented for men and women separately. Also
HDL cholestorol was notmeasured in these surveys. In none of
the participating studies a significant association between
cholesterol and fatal stroke was observed: the odds ratio per
1.0 mmol/l in cholesterol increase varied between 0.80 and
1.40.11 We confirm these findings and expand these results to
non-fatal stroke and to cerebral infarction.
We could not disclose a direct positive association between
cholesterol and stroke or cerebral infarction. Also, when a cut
off point of 8.0 mmol/l was used, no association was found.
Some studies have reported an inverse association between
cholesterol and haemorrhagic stroke, in which the risk of
haemorrhagic stroke was particularly increased in subjects
with a cholesterol level below 4.0 mmol/l.We found an inverse
association with haemorrhagic stroke, which, however, did
not achieve statistical significance. Yet, those in the upper
quartile of the total cholesterol distribution had a significantly
lower risk of stroke compared with those in the lower quartile.
In this study the number of haemorrhagic strokes among
subjects with cholesterol levels below 4.0 mmol/l was too
small to reliably evaluate the associations.
Several explanations have been given for the absence of an
association between cholesterol and stroke. Firstly, in studies
where only total stroke is considered, a positive association
between increased cholesterol and cerebral infarction may be
counterbalanced by the inverse association between low chol-
esterol and cerebral haemorrhage. This may be particular rel-
evant for fatal stroke because mortality from haemorrhage is
generally higher than from cerebral infarction, which leads to
a higher proportion of haemorrhagic stroke among the fatal
cases. However, in our study no association was found with
fatal and non-fatal stroke, nor with the type of stroke.
Secondly, as stroke and coronary heart disease share risk fac-
tors, an attenuation of the association with cholesterol may be
attributable to competing of coronary heart disease. Stroke
typically occurs later in life than coronary heart disease, prob-
ably because of the time related development of atheroscle-
rotic lesions first in the aorta, then in the coronary arteries and
finally in the cerebral arteries. When in populations the
incidence of coronary heart disease early in life is relatively
higher than that of stroke, the association with stroke may be
attenuated. Many people with increased cholesterol may die
from coronary heart disease before a stroke can occur. This
leaves subjects at risk of stroke with either moderately
increased cholesterol levels or subjects with high cholesterol
levels whose cardiovascular system for some reason is
relatively resistant to high cholesterol. Thirdly, subjects who
survive a myocardial infarction, or who suffer from severe
anginamay undergo radical risk factor intervention to prevent
further atherosclerotic events from occurring. This may
further attenuate the association between cholesterol and
stroke. Finally, it should be noted that the importance of one
risk factor is relative to the presence of other potential factors
contributing to the disease of interest. In industrialised socie-
ties, smoking, increased blood pressure, diabetes mellitus may
reduce the relative importance of increased cholesterol as a
risk factor for stroke. However, in our analyses the finding for
total cholesterol and HDL cholesterol and stroke were not dif-
ferent in the full model compared with the age and sex
adjusted model. In addition, this reasoning is exemplified in a
published risk score to estimate an individual’s risk of stroke
within 10 years, in which serum lipids were not included.13
In an overview of results of trials on the efficacy of choles-
terol lowering, a significant reduction in fatal or non-fatal
stroke incidence with lipid lowering regimens compared with
placebo treatment could not be demonstrated.36 In a recent
trial among 6595 men free from myocardial infarction at
baseline and with increased cholesterol levels, in which chol-
esterol lowering was achieved through a newer lipid lowering
drug (hydroxy-methylglutaryl-coenzyme A reductase inhibi-
tor) a non-significant reduction of 11% in risk of fatal and
non-fatal stroke was observed.37 In the 4S trial among 4444
subjects with previous coronary heart disease and increased
cholesterol levels, lipid lowering with a HMG-CoA reductase
inhibitor resulted in a significant 30% reduction in cerebrovas-
cular events (fatal and non-fatal stroke, and transient ischae-
mic attacks).38 All these trials were not specifically designed to
assess the efficacy of lipid lowering in the reduction of fatal
and non-fatal stroke, in particular they did not have the
appropriate sample size.39 Their results support the view that
the relation of cholesterol with stroke is not as strong as with
coronary heart disease. The beneficial effect of cholesterol
lowering on stroke in the two recent trials may be attributable
to reduced progression (or regression) of atherosclerosis or,
more probably, to the prevention of secondary effects of myo-
cardial infarction—that is, embolic stroke or transient ischae-
mic attacks.
Few prospective population-based studies have examined
the association between HDL cholesterol and stroke. Those
available were of the same sample size as this study. In general
the results from these studies showed a tendency towards a
increased risk of cerebral infarction with lower levels of HDL
cholesterol. In these studies a decrease of 0.26 mmol/l was
associated with odds ratios between 1.08 and 1.18. In our
Table 4 HDL cholesterol and risk of stroke in quartiles of the distribution
First quartile Second quartile Third quartile Fourth quartile
Stroke Cases Cases Cases Cases Trend†
Men*
All 77 1.0 47 0.79 (0.51 to 1.26) 63 0.98 (0.61 to 1.57) 28 0.71 (0.44 to 1.14) 0.71 (0.42 to 1.20)
Fatal 17 1.0 10 0.65 (0.27 to 1.54) 10 0.57 (0.21 to 1.51) 9 0.86 (0.37 to 1.95) 0.90 (0.33 to 2.41)
Non-fatal 10 1.0 37 0.82 (0.50 to 1.34) 53 1.10 (0.67 to 1.82) 19 0.65 (0.38 to 1.11) 0.66 (0.37 to 1.19)
Haemorrhagic 8 1.0 8 0.85 (0.29 to 2.47) 6 0.67 (0.19 to 2.37) 8 1.35 (0.51 to 3.57) 1.20 (0.40 to 3.63)
Ischaemic 56 1.0 34 0.79 (0.47 to 1.32) 50 1.16 (0.70 to 1.92) 16 0.56 (0.32 to 0.98) 0.65 (0.35 to 1.19)
Ischaemic‡ 69 1.0 39 0.77 (0.48 to 1.24) 57 1.01 (0.62 to 1.64) 20 0.60 (0.36 to 1.00) 0.62 (0.35 to 1.12)
Women*
All 17 1.0 13 0.62 (0.29 to 1.33) 26 1.15 (0.54 to 2.43) 49 1.27 (0.65 to 2.47) 1.93 (1.00 to 3.70)
Fatal 5 1.0 7 0.74 (0.18 to 2.96) 8 1.83 (0.53 to 6.33) 12 0.73 (0.21 to 2.59) 0.87 (0.22 to 3.27)
Non-fatal 12 1.0 6 0.62 (0.26 to 1.44) 18 0.99 (0.42 to 2.35) 37 1.49 (0.72 to 3.09) 2.46 (1.20 to 5.04)
Haemorrhagic 1 1.0 2 No cases 2 1.97 (0.38 to 10.1) 6 1.18 (0.24 to 5.85) 1.49 (0.26 to 8.67)
Ischaemic 9 1.0 6 0.74 (0.30 to 1.85) 18 1.21 (0.48 to 3.07) 29 1.63 (0.73 to 3.64) 2.52 ( 1.15 to 5.50)
Ischaemic‡ 16 1.0 11 0.68 (0.31 to 1.50) 23 1.06 (0.47 to 2.37) 43 1.32 (0.66 to 2.64) 2.02 (1.02 to 4.01)
Odds ratios with 95% CI relative to the first quartile of HDL cholesterol, adjusted for age, body mass index, systolic blood pressure, curent smoking and
diabetes mellitus. The number of controls among men in the respective quartiles were 162, 103, 154, 91. The number of controls among women in the
respective quartiles were 46, 33, 115, 121. *Cut off points were 0.95, 1.16 and 1.37 mmol/l for men and; 1.12, 1.35 and 1.60 mmol/l for women;
†trends: odds ratio per 1 mmol/l increase in HDL cholesterol; ‡ischaemic stroke including unspecified stroke events.
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study such an analyses would show a non-significant odds
ratio of 1.09 and therefore be compatible with these reports, at
least for men. Surprisingly, a high HDL cholesterol in women
conferred an increased risk of stroke in the present analysis, in
particular among smokers and non-smokers. This finding has
not been reported before and is in contrast with the available
evidence relating high HDL levels to beneficial changes in
carotid atherosclerosis and cardiovascular disease. Therefore,
further studies are need to confirm this finding.
In conclusion, this analysis of the EUROSTROKE project
could not disclose an association of total cholesterol with fatal,
non-fatal, haemorrhagic or ischaemic stroke. HDL cholesterol
however, seemed to be related to stroke differently in men
than in women.
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